Q2 2026 revenue exceeded guidance at $145 million, with improved cost discipline and a net loss of $782 million. Pipeline advanced with key regulatory milestones in flu and RSV vaccines, and oncology programs showed durable benefit. Revenue growth of up to 10% is expected for 2026.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.